Samik Pharm Co Ltd

Samik Pharm Co Ltd has a market price of 8,980 KRW and a market cap of 82,567,813,320 KRW, with a price-to-book ratio of 1.2 and a price-to-tangible-book ratio of 1.2. The company's enterprise value to EBITDA is 26.15, and its enterprise value to revenue is 1.43. The company's liquidity position is characterized by a current ratio of 4.85, but it has negative net cash after subtracting total debt. The company's profitability metrics show a return on equity of -1.09% and a return on assets of -0.89%, both of which are below the typical thresholds for pharmaceutical firms. The operating income of 3,272,885,600 KRW is significantly lower than the gross profit of 42,359,589,780 KRW, indicating high operating expenses or low operating margins. Samik Pharm Co Ltd's revenue is derived from a range of pharmaceutical products, including circulatory treatments, diabetes treatments, digestive treatments, and antipyretic anti-inflammatory drugs. The company's geographic exposure is primarily domestic, with some overseas sales, but the exact revenue concentration by region is not disclosed in the available data. The company's growth trajectory is mixed, with a net income of -754,888,320 KRW and a free cash flow of -3,096,705,570 KRW. The capital expenditure of -3,431,506,020 KRW suggests significant investment in operations, but the negative free cash flow indicates that the company is not generating sufficient cash to cover its capital needs. The risk assessment for Samik Pharm Co Ltd highlights a medium liquidity risk and a low dilution risk. The company's key financial flags include negative net cash after subtracting total debt, which could impact its ability to meet short-term obligations. The dilution potential is low, with no significant changes in shares outstanding between basic and diluted shares. Recent financial filings and transcripts do not provide additional insights into the company's operations or strategic direction. The company's financial performance and risk profile suggest a need for close monitoring of its liquidity and profitability metrics to assess its long-term viability.